Trial Profile
Beta Cell Rescue in New Onset Type 1 Diabetes Mellitus With the LFA-1 Antibody Efalizumab.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms BRiTE
- 20 May 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual start date (Oct 2008) added as reported by ClinicalTrials.gov.